| Utility of physiologically based biopharmaceutics modeling (PBBM) in Regulatory Perspective: application to Supersede f2, enabling Biowaivers & Creation of Dissolution Safe Space AK Bhattiprolu, S Kollipara, T Ahmed, R Boddu, S Chachad Journal of Pharmaceutical Sciences 111 (12), 3397-3410, 2022 | 26 | 2022 |
| Best practices for integration of dissolution data into physiologically based biopharmaceutics models (PBBM): a biopharmaceutics modeling scientist perspective S Kollipara, AK Bhattiprolu, R Boddu, T Ahmed, S Chachad AAPS PharmSciTech 24 (2), 59, 2023 | 24 | 2023 |
| Simplified model-dependent and model-independent approaches for dissolution profile comparison for oral products: regulatory perspective for generic product development S Kollipara, R Boddu, T Ahmed, S Chachad AAPS PharmSciTech 23 (1), 53, 2022 | 21 | 2022 |
| Biopharmaceutics Risk Assessment—Connecting Critical Bioavailability Attributes with In Vitro,In Vivo Properties and Physiologically Based Biopharmaceutics … T Ahmed, S Kollipara, R Boddu, AK Bhattiprolu The AAPS Journal 25 (5), 77, 2023 | 17 | 2023 |
| Dissolution studies and quantification of meloxicam in tablet dosage form by spectrophotometry. M Induri, BR Mantripragada, RP Yejella, PR Kunda, DT Nannapaneni, ... Pakistan journal of pharmaceutical sciences 25 (1), 2012 | 12 | 2012 |
| A validated RP-HPLC method for the quantification of zolmitriptan in tablet dosage form M Induri, RM Bhagavan, PY Rajendra, RK Pavankumar, R Boddu, ... Der Pharma Chemica 2 (5), 351-357, 2010 | 12 | 2010 |
| Power of integrating PBPK with PBBM (PBPK-BM): a single model predicting food effect, gender impact, drug-drug interactions and bioequivalence in fasting & fed conditions R Boddu, S Kollipara, G Vijaywargi, T Ahmed Xenobiotica 53 (4), 260-278, 2023 | 10 | 2023 |
| Simultaneous quantification of paracetamol and meloxicam in tablets by high performance liquid chromatography M Induri, BR Mantripragada, RP Yejella, PR Kunda, M Arugula, R Boddu Tropical Journal of Pharmaceutical Research 10 (4), 475-481, 2011 | 10 | 2011 |
| Novel application of PBBM to justify impact of faster dissolution on safety and pharmacokinetics–a case study and utility in regulatory justifications R Boddu, S Kollipara, AK Bhattiprolu, T Ahmed Xenobiotica 53 (10-11), 587-602, 2023 | 7 | 2023 |
| Development of an in vitro-in vivo correlation for sitagliptin and metformin prolonged-release tablet formulations R Boddu, HC Vadla, VR Prathap, U Kothamasu, BC Rallabandi, R Gannu Turkish Journal of Pharmaceutical Sciences 18 (2), 233, 2021 | 5 | 2021 |
| A semi-mechanistic physiologically based biopharmaceutics model to describe complex and saturable absorption of metformin: justification of dissolution specifications for … AK Bhattiprolu, S Kollipara, R Boddu, A Arumugam, SM Khan, T Ahmed AAPS PharmSciTech 25 (7), 193, 2024 | 3 | 2024 |
| Experience on Utilization of Novel Modeling & Simulation Approaches in Generic Product Development R Boddu, S Kollipara, A Rachapally, T Ahmed Journal ISSN 2766, 2276, 2024 | 3 | 2024 |
| Dissolution Profiles Comparison Using Conventional and Bias Corrected and Accelerated f2 Bootstrap Approaches with Different Software’s: Impact of Variability, Sample Size and … R Boddu, S Kollipara, AK Bhattiprolu, K Parsa, SK Chakilam, KR Daka, ... AAPS PharmSciTech 25 (1), 5, 2023 | 3 | 2023 |
| Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development R Boddu, S Kollipara, V Kambam, SM Khan, S Behera, NN Murty, ... Xenobiotica 54 (9), 629-641, 2024 | 1 | 2024 |
| Playing Hide-and-Seek with Tyrosine Kinase Inhibitors: Can We Overcome Administration Challenges? S Kollipara, M Chougule, R Boddu, A Bhatia, T Ahmed The AAPS Journal 26 (4), 66, 2024 | 1 | 2024 |
| Identification of Phases of Various Oil, Surfactant/Co-Surfactants and Water System by Ternary Phase Diagram R Boddu, KVR Murthy Journal of Pharmaceutical and Biological Sciences 3 (6), 261, 2015 | 1 | 2015 |
| Justification of widened dissolution specifications of an extended-release product using physiologically based biopharmaceutics modeling AK Bhattiprolu, S Kollipara, R Boddu, T Ahmed Xenobiotica 54 (10), 781-795, 2024 | | 2024 |
| Demonstrating Discriminatory Power of a Dissolution Method Using DDDPlus: Case Study of an Extended-Release Formulation and Use in Regulatory Justifications S Kollipara, AK Bhattiprolu, R Boddu, M Chougule, P Saha, T Ahmed | | 2024 |
| Bioequivalence Requirements for Orally Inhaled and Nasal Drug Products and Use of Novel Physiologically Based Biopharmaceutics Modeling Approaches for Assessing In Vivo Performance A Rachapally, R Boddu, S Kollipara, T Ahmed Journal of Pharmaceutical Sciences, 2024 | | 2024 |
| Model Independent and Dependent Methods for Dissolution Profiles Comparison: Can we take the Road Less Travelled? AK Bhattiprolu, S Kollipara, R Boddu, A Rachapally, T Ahmed International Journal of Pharmaceutical Sciences and Developmental Research …, 2024 | | 2024 |
